JP5864819B2 - 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物 - Google Patents

精神的障害、行動障害および認知障害の予防および治療のための医薬組成物 Download PDF

Info

Publication number
JP5864819B2
JP5864819B2 JP2015513964A JP2015513964A JP5864819B2 JP 5864819 B2 JP5864819 B2 JP 5864819B2 JP 2015513964 A JP2015513964 A JP 2015513964A JP 2015513964 A JP2015513964 A JP 2015513964A JP 5864819 B2 JP5864819 B2 JP 5864819B2
Authority
JP
Japan
Prior art keywords
melatonin
weight
memantine
pharmaceutical composition
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015513964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517569A (ja
Inventor
モロゾワ，マルガリータ，アレクセーエヴナ
バティアシュヴィリ，アラン，ゲロヴィッチ
ザポリスキー，マキシム，エドゥアルドヴィッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valenta Intellect LLC
Original Assignee
Valenta Intellect LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellect LLC filed Critical Valenta Intellect LLC
Publication of JP2015517569A publication Critical patent/JP2015517569A/ja
Application granted granted Critical
Publication of JP5864819B2 publication Critical patent/JP5864819B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015513964A 2012-05-24 2012-10-31 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物 Expired - Fee Related JP5864819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012121410 2012-05-24
RU2012121410/15A RU2488388C1 (ru) 2012-05-24 2012-05-24 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PCT/RU2012/000888 WO2013176567A1 (ru) 2012-05-24 2012-10-31 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Publications (2)

Publication Number Publication Date
JP2015517569A JP2015517569A (ja) 2015-06-22
JP5864819B2 true JP5864819B2 (ja) 2016-02-17

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513964A Expired - Fee Related JP5864819B2 (ja) 2012-05-24 2012-10-31 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物

Country Status (14)

Country Link
US (1) US20150157604A1 (cg-RX-API-DMAC10.html)
EP (1) EP2857011A4 (cg-RX-API-DMAC10.html)
JP (1) JP5864819B2 (cg-RX-API-DMAC10.html)
KR (1) KR101581611B1 (cg-RX-API-DMAC10.html)
CN (1) CN104334166A (cg-RX-API-DMAC10.html)
AU (1) AU2012380583B2 (cg-RX-API-DMAC10.html)
CA (1) CA2873891C (cg-RX-API-DMAC10.html)
EA (1) EA201400973A1 (cg-RX-API-DMAC10.html)
HK (1) HK1205467A1 (cg-RX-API-DMAC10.html)
IL (1) IL235852A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN09940A (cg-RX-API-DMAC10.html)
RU (1) RU2488388C1 (cg-RX-API-DMAC10.html)
UA (1) UA112352C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013176567A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (ru) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
EP3383482B1 (en) 2015-11-24 2023-01-04 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
KR102280457B1 (ko) * 2016-06-29 2021-07-23 엘티디 "발렌타-인텔렉트" 메만틴 및 멜라토닌의 배합물을 함유하는 약제학적 조성물
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
CA3044440A1 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (cg-RX-API-DMAC10.html) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1562585T3 (da) 2002-10-30 2011-03-14 Asat Ag Applied Science & Tech Daglige melatonindoseringsenheder
RU2268737C2 (ru) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
JP2008504372A (ja) * 2004-06-18 2008-02-14 ニューロケム （インターナショナル） リミティッド β−アミロイド関連疾患の治療のための治療用製剤
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
MY148806A (en) * 2005-04-04 2013-05-31 Takeda Pharmaceutical Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia
CN1709230A (zh) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚分散片及其制备方法
RU2294741C1 (ru) 2005-08-08 2007-03-10 Рина Михайловна Заславская Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
JP2009538334A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
CA2684213A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
NZ594207A (en) * 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
RU2394571C1 (ru) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Способ лечения воспалительных заболеваний кишечника
RU2418586C2 (ru) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой
RU2428183C1 (ru) 2010-07-01 2011-09-10 Рина Михайловна Заславская Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена

Also Published As

Publication number Publication date
KR20150005999A (ko) 2015-01-15
EP2857011A4 (en) 2015-12-02
IN2014DN09940A (cg-RX-API-DMAC10.html) 2015-08-14
KR101581611B1 (ko) 2015-12-31
CA2873891C (en) 2016-02-16
UA112352C2 (uk) 2016-08-25
WO2013176567A1 (ru) 2013-11-28
JP2015517569A (ja) 2015-06-22
CA2873891A1 (en) 2013-11-28
RU2488388C1 (ru) 2013-07-27
US20150157604A1 (en) 2015-06-11
CN104334166A (zh) 2015-02-04
AU2012380583A1 (en) 2014-12-18
IL235852A0 (en) 2015-01-29
EA201400973A1 (ru) 2015-02-27
EP2857011A1 (en) 2015-04-08
AU2012380583B2 (en) 2015-01-22
HK1205467A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
JP2015517569A (ja) 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
CN114340670A (zh) T-型钙通道调节剂的制剂及其使用方法
EP3200772B1 (en) Pharmaceutical compositions comprising alpelisib
EP3424499B1 (en) A pharmaceutical composition for neuropathic pain
CN115776894A (zh) T型钙通道调节剂的使用方法
WO2016029868A1 (zh) 用于减少体重及减少体脂肪的组合物及其医药品与应用
KR20250069704A (ko) 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
KR20170137910A (ko) 제약 분야에서의 r―옥시라세탐 응용
CA2993614A1 (en) Combination therapy using acamprosate and d-cycloserine
US20030171391A1 (en) Ambroxol for the treatment of chronic pain
CN121370879A (zh) 治疗边缘型人格障碍的方法
CN120837494A (zh) 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
US9999614B2 (en) Combination for the prophylaxis and treatment of behavioural, mental, and cognitive disorders
HK40084155A (en) Pharmaceutical compositions comprising alpelisib
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
CN115531326A (zh) 一种卡巴拉汀微片及其制备方法
JPH02500746A (ja) 鎮痛剤
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
WO2021260636A1 (en) A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150205

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150205

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151224

R150 Certificate of patent or registration of utility model

Ref document number: 5864819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees